| Nr. | Year OPEN | Title | users say> | rate good | rate bad | no link | Citation |
Iron (Chelator)Myelodysplastic syndromeThalassemia| 1 | 2005 | The evolution of iron chelators for the treatment of iron overload disease and cancer. | 
| + | - | nl | Pharmacol Rev 57(4):547-83 (2005) |
| 2 | 2008 | Clinical application of deferasirox: practical patient management. | 
| + | - | nl | Am J Hematol 83(5):398-402 (2008) |
| 3 | 2003 | Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. | 
| + | - | nl | Am J Hematol 73(3):200-10 (2003) |
| 4 | 2009 | Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? | 
| + | - | nl | Blood 114(26):5251-5 (2009) |
| 5 | 2010 | Update on iron chelators in thalassemia. | 
| + | - | nl | Hematology Am Soc Hematol Educ Program 2010(-):451-5 (2010) |
| 6 | 2011 | Iron-chelating therapy for transfusional iron overload. | 
| + | - | nl | N Engl J Med 364(2):146-56 (2011) |